STAAR SURGICAL CO (STAA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, STAAR SURGICAL CO's filing signal continuing negative.

STAAR Surgical Company is a global leader in the design, development, manufacturing, and sale of implantable lenses for the eye, primarily focusing on its proprietary Implantable Collamer Lenses (ICLs) for refractive surgery. The company's ICLs, made from a unique collagen copolymer material, are implanted without removing the natural crystalline lens and are foldable for minimally invasive surgery. STAAR's flagship product line, the EVO family of lenses, treats myopia and presbyopia, with the EVO ICL being the only foldable, minimally invasive posterior chamber phakic intraocular lens approved for sale in the U.S. and reportedly the world's largest selling phakic IOL. The company operates globally, with 91% of its revenue generated from international sales across over 85 countries, maintaining operational and administrative facilities in the U.S., Switzerland, and Japan. STAAR's commercialization strategy centers on making its complete ICL product line available in existing markets and expanding into new ones, while also focusing on surgeon training and awareness of the ICL procedure.

Revenue is almost exclusively driven by sales of Implantable Collamer Lenses (ICLs) used in refractive surgery. The company also generates minor revenue from delivery systems and sales adjustments.